Arcturus Therapeutics Holdings (ARCT) Enterprise Value (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed Enterprise Value for 8 consecutive years, with -$230.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 20.93% year-over-year to -$230.9 million, compared with a TTM value of -$230.9 million through Dec 2025, up 20.93%, and an annual FY2025 reading of -$230.9 million, up 20.93% over the prior year.
- Enterprise Value was -$230.9 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$235.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$55.0 million in Q2 2025 and bottomed at -$466.8 million in Q1 2021.
- Average Enterprise Value over 5 years is -$321.4 million, with a median of -$323.5 million recorded in 2023.
- The sharpest move saw Enterprise Value crashed 684.99% in 2021, then surged 82.56% in 2025.
- Year by year, Enterprise Value stood at -$370.5 million in 2021, then decreased by 5.77% to -$391.9 million in 2022, then grew by 11.45% to -$347.0 million in 2023, then increased by 15.84% to -$292.0 million in 2024, then grew by 20.93% to -$230.9 million in 2025.
- Business Quant data shows Enterprise Value for ARCT at -$230.9 million in Q4 2025, -$235.4 million in Q3 2025, and -$55.0 million in Q2 2025.